What does the future hold for cholesteryl ester transfer protein inhibition?

Current Opinion in Lipidology
Benoit J ArsenaultJohn J P Kastelein

Abstract

This article summarizes the latest studies relevant to cholesteryl ester transfer protein (CETP) inhibition and cardiovascular risk and proposes a series of patient populations that might eventually derive benefits from CETP inhibition. Results of recently published genetic epidemiology studies have helped shape our understanding of the association between lipoprotein-lipid levels and cardiovascular disease risk. These studies have confirmed the proatherogenic role of apolipoprotein B-containing lipoproteins and triglycerides and renewed our interest for lipoprotein(a) as a significant and causal predictor of cardiovascular risk. The association between HDL cholesterol levels and cardiovascular risk, albeit strong and consistent, is unlikely to be of causative nature, at least according to genetic epidemiology. However, a handful of intriguing studies have highlighted a predictive role for HDL cholesterol efflux capacities in predicting cardiovascular risk independently of HDL cholesterol levels. Potent CETP inhibitors, currently under investigation, significantly decrease apolipoprotein B-containing lipoproteins and lipoprotein(a) and increase both HDL cholesterol levels and HDL cholesterol efflux capacities. Two phase 3 cardi...Continue Reading

References

Jul 1, 1992·The Journal of Clinical Investigation·E BoerwinkleH H Hobbs
Dec 5, 1998·The New England Journal of Medicine·UNKNOWN Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
Oct 16, 2003·JAMA : the Journal of the American Medical Association·Nir BarzilaiAlan R Shuldiner
Jun 10, 2005·The New England Journal of Medicine·S Joanna CowellUNKNOWN Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression (SALTIRE) Investigators
Mar 24, 2006·The New England Journal of Medicine·Jonathan C CohenHelen H Hobbs
Jun 6, 2006·Journal of the American College of Cardiology·Martin BriandPhilippe Pibarot
Nov 7, 2007·The New England Journal of Medicine·Philip J BarterUNKNOWN ILLUMINATE Investigators
Jun 4, 2008·Circulation·John J P KasteleinUNKNOWN IDEAL Study Group
Jun 19, 2008·JAMA : the Journal of the American Medical Association·Alexander ThompsonJohn Danesh
Sep 4, 2008·The New England Journal of Medicine·Anne B RossebøUNKNOWN SEAS Investigators
Sep 26, 2008·The New England Journal of Medicine·Catherine M Otto
Jun 11, 2009·JAMA : the Journal of the American Medical Association·Pia R KamstrupBørge G Nordestgaard
Jul 23, 2009·JAMA : the Journal of the American Medical Association·UNKNOWN Emerging Risk Factors CollaborationJohn Danesh
Dec 25, 2009·The New England Journal of Medicine·Robert ClarkeUNKNOWN PROCARDIS Consortium
Apr 14, 2010·Proceedings of the National Academy of Sciences of the United States of America·Wei ChenAnand Swaroop
May 15, 2010·Arteriosclerosis, Thrombosis, and Vascular Biology·Michelle A FryirsKerry-Anne Rye
Oct 23, 2010·European Heart Journal·Børge G NordestgaardUNKNOWN European Atherosclerosis Society Consensus Panel
Nov 19, 2010·The New England Journal of Medicine·Christopher P CannonUNKNOWN Determining the Efficacy and Tolerability Investigators
Jan 14, 2011·The New England Journal of Medicine·Amit V KheraDaniel J Rader
Feb 2, 2011·Nature Reviews. Cardiology·Benoit J ArsenaultJohn J P Kastelein
Nov 17, 2011·The New England Journal of Medicine·William E BodenWilliam Weintraub
Jul 14, 2012·Journal of the American College of Cardiology·Romain CapouladeUNKNOWN ASTRONOMER Investigators
Sep 25, 2012·Journal of Internal Medicine·F Kronenberg, G Utermann
Oct 23, 2012·Journal of the American College of Cardiology·Trine Holm JohannsenAnne Tybjærg-Hansen
Nov 7, 2012·The New England Journal of Medicine·Gregory G SchwartzUNKNOWN dal-OUTCOMES Investigators
Dec 4, 2012·Nature Genetics·Panos DeloukasNilesh J Samani
Dec 26, 2012·Journal of the American College of Cardiology·Anette VarboBørge G Nordestgaard
Feb 2, 2013·Arteriosclerosis, Thrombosis, and Vascular Biology·Elise F VillardMaryse Guerin
Feb 8, 2013·The New England Journal of Medicine·George ThanassoulisUNKNOWN CHARGE Extracoronary Calcium Working Group
Mar 23, 2013·Arteriosclerosis, Thrombosis, and Vascular Biology·Xin-Min LiStanley L Hazen

❮ Previous
Next ❯

Citations

May 8, 2016·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Charles L BisgaierDaniel Hartman

❮ Previous
Next ❯

Methods Mentioned

BETA
pharmacotherapy
antisense oligonucleotide

Clinical Trials Mentioned

NCT01252953
NCT01687998

Software Mentioned

ACCELERATE
DEFINE

Related Concepts

Related Feeds

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.